Drug Delivery Technologies: Commercial Prospects 2013-2023
Drug delivery technology - discover technological and commercial prospects
What does the future hold for drug delivery technologies? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions. Many commercial opportunities for improved drug delivery exist. You discover sales predictions to 2023 at world market, submarket, application and national level.
Forecasts and other analyses to help you stay ahead in knowledge
In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. You see qualitative analysis (SWOT analysis), business news, outlooks and developmental trends. You gain 59 tables, 34 charts and 7 research interviews.
Is finding commercial details a challenge? With our report you can get ahead in knowledge, benefiting your research, analyses and decisions. Discover areas that will prosper, reducing the risk of your being left behind.
You discover industry dynamics and growth potentials - the following sections show what you find in our new report.
Discover prospects for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2023 for these submarkets:
How will biological drugs using the technologies perform from 2013? You find overall revenues from nine pharmaceutical areas predicted to 2023:
Drug delivery R&D is promising. Suppliers and users of the technology will benefit. Our calculations show you the potential for expanded revenues to 2023.
Which areas of pharma will benefit most? Drug delivery technologies offer many opportunities for pharma line extensions and product lifecycle management, benefiting a wide range of drugs. Biologicals and vaccines will profit especially. You see how.
In our analysis, the drug delivery technology industry will achieve high revenue growth from 2013 to 2023. In particular, greater use of injectable drugs and vaccines worldwide will stimulate demand for innovative delivery systems.
We find wide scope for novel and improved drug delivery from 2013 onwards, seeing many sales opportunities for products and services there. Our report explains.
Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations and presentations. You find answers in our work.
What prospects for leading regions and countries?
Developments worldwide will influence the market from 2013, especially the expansion of healthcare in emerging countries. There exist many opportunities for companies developing drug delivery technologies. Market growth will be driven by opportunities in biological drug and vaccine sectors. See prospects for the industry.
You get individual forecasts to 2023 for nine national markets, finding overall revenues:
Eight ways Drug Delivery Technologies: Commercial Prospects 2013-2023 helps
To sum up, our investigation gives you the following knowledge:
That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative and growth is likely.
With our report you are less likely to fall behind in knowledge or miss opportunity. See how our work could benefit your research, analyses and decisions, saving you time and getting you recognition for commercial insight.
Discover technological and commercial prospects from 2013 by ordering now
Our study is for everybody needing industry and market analyses for drug delivery technologies. You find data, trends and answers there. Avoid missing out - please order our report now.
What does the future hold for drug delivery technologies? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions. Many commercial opportunities for improved drug delivery exist. You discover sales predictions to 2023 at world market, submarket, application and national level.
Forecasts and other analyses to help you stay ahead in knowledge
In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. You see qualitative analysis (SWOT analysis), business news, outlooks and developmental trends. You gain 59 tables, 34 charts and 7 research interviews.
Is finding commercial details a challenge? With our report you can get ahead in knowledge, benefiting your research, analyses and decisions. Discover areas that will prosper, reducing the risk of your being left behind.
You discover industry dynamics and growth potentials - the following sections show what you find in our new report.
Discover prospects for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2023 for these submarkets:
- Oral delivery
- Inhaled delivery
- Transdermal delivery
- Ocular delivery
- Nasal delivery
- Implants for drug delivery
How will biological drugs using the technologies perform from 2013? You find overall revenues from nine pharmaceutical areas predicted to 2023:
- Monoclonal antibodies
- Insulins
- Erythropoietins
- Interferons
- G-CSF agents
- Recombinant coagulation factors
- Other therapeutic proteins
- Biosimilars and related agents
- Vaccines.
Drug delivery R&D is promising. Suppliers and users of the technology will benefit. Our calculations show you the potential for expanded revenues to 2023.
Which areas of pharma will benefit most? Drug delivery technologies offer many opportunities for pharma line extensions and product lifecycle management, benefiting a wide range of drugs. Biologicals and vaccines will profit especially. You see how.
In our analysis, the drug delivery technology industry will achieve high revenue growth from 2013 to 2023. In particular, greater use of injectable drugs and vaccines worldwide will stimulate demand for innovative delivery systems.
We find wide scope for novel and improved drug delivery from 2013 onwards, seeing many sales opportunities for products and services there. Our report explains.
Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations and presentations. You find answers in our work.
What prospects for leading regions and countries?
Developments worldwide will influence the market from 2013, especially the expansion of healthcare in emerging countries. There exist many opportunities for companies developing drug delivery technologies. Market growth will be driven by opportunities in biological drug and vaccine sectors. See prospects for the industry.
You get individual forecasts to 2023 for nine national markets, finding overall revenues:
- US
- Japan
- Germany, France, UK, Italy and Spain
- India and China.
Eight ways Drug Delivery Technologies: Commercial Prospects 2013-2023 helps
To sum up, our investigation gives you the following knowledge:
- Revenues to 2023 for the overall world market and 6 submarkets - you discover that industry's prospects
- Forecasting to 2023 for the US, Japan, Germany, France, UK, Spain, Italy, India and China - you see leading national sales potentials
- Assessments of biological drug markets - discover prospects for drug delivery technologies from 2013
- Assessments of leading companies - you find activities, products, capabilities and outlooks
- Opinions on the sector - you read our industry interviews
- Understanding of competition and opportunities - you see what affects that industry, learning what shapes its future
- Analysis of what stimulates and restrains the industry and market - you assess challenges and strengths
- Prospects for established firms and those seeking to enter the sector - you explore needs, practices and outlooks for success.
That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative and growth is likely.
With our report you are less likely to fall behind in knowledge or miss opportunity. See how our work could benefit your research, analyses and decisions, saving you time and getting you recognition for commercial insight.
Discover technological and commercial prospects from 2013 by ordering now
Our study is for everybody needing industry and market analyses for drug delivery technologies. You find data, trends and answers there. Avoid missing out - please order our report now.
1. EXECUTIVE SUMMARY
1.1 Drug Delivery Technology: Market Review
1.2 Aims, Scope and Format of Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods
2. INTRODUCTION
2.1 Introduction to Drug Delivery Technologies (DDT)
2.2 Types of Technologies for Drug Delivery
2.2.1 Sustained/Controlled Release Systems
2.2.2 Injection
2.2.3 Needle Free Injection
2.2.4 Pulmonary, Buccal and Nasal Delivery
2.2.5 Pills and Capsules
2.3 Biopharmaceuticals
2.3.1 Overview of the Biologicals Market
2.3.2 The Biological Drug Industry is Strong
2.4 Biotech Drugs with Associated Drug Delivery Technologies
2.4.1 Pegylated Interferons
2.4.2 Crowded Insulin Market Has Forced Investment in DDT
2.5 Exubera - Case Study for Alternative Biological Delivery Methods
2.5.1 The First Inhaled Insulin
2.5.2 Description and Development History
2.5.3 Generex and MannKind Developing Next-Generation Oral Insulins
2.5.4 Challenges Facing Afrezza and Oral-lyn
2.6 The Main Challenges for Biological Drug Delivery
3. THE WORLD DRUG DELIVERY TECHNOLOGY MARKET TO 2023
3.1 The World Drug Delivery Technology Market: Overview
3.2 Growing Market for Drug Delivery Technology and Services
3.2.1 Revenue Forecast for Overall Drug Delivery Technology Market, 2012-2017
3.2.2 Revenue Forecast for Overall Drug Delivery Market, 2018-2023
3.3 Breakdown of the Global Drug Delivery Technology Market
3.3.1 Revenue Forecast for Oral Drug Delivery Technology, 2012-2017
3.3.2 Revenue Forecast for Oral Drug Delivery Technology, 2018-2023
3.3.3 Revenue Forecast for Inhalation Drug Delivery Technology, 2012-2017
3.3.4 Revenue Forecast for Inhalation Drug Delivery Technology, 2018-2023
3.3.5 Revenue Forecast for Transdermal Drug Delivery Technology, 2012-2017
3.3.6 Revenue Forecast for Transdermal Drug Delivery Technology, 2018-2023
3.3.7 Revenue Forecast for Injectable/Implants Drug Delivery Technology, 2012-2017
3.3.8 Revenue Forecast for Injectable/Implants Drug Delivery Technology, 2018-2023
3.3.9 Revenue Forecast for Ocular Drug Delivery Technology, 2012-2017
3.3.10 Revenue Forecast for Ocular Drug Delivery Technology, 2018-2023
3.3.11 Revenue Forecast for Nasal Drug Delivery Technology, 2012-2017
3.3.12 Revenue Forecast for Nasal Drug Delivery Technology, 2018-2023
3.4 Leading National Markets for Drug Delivery Technology
3.4.1 The US Drug Delivery Technology Market, 2013-2023
3.4.2 The Japanese Drug Delivery Technology Market, 2013-2023
3.4.3 The Leading European Drug Delivery Technology Markets, 2013-2023
3.4.4 Emerging-Economy Drug Delivery Technology Markets
3.4.5 The Chinese Drug Delivery Technology Market, 2013-2023
3.4.6 The Indian Drug Delivery Technology Market, 2013-2023
4. DRUG CLASSES THAT CAN BENEFIT FROM ADVANCES IN DRUG DELIVERY
4.1 Therapeutic Areas Offering Growth Opportunities
4.1.1 Sales of Biologics Will Stimulate Developments in Drug Delivery
4.1.2 Leading Segments of Biological Drugs Market in 2012
4.1.3 Monoclonal Antibodies Lead the Biologics Market
4.1.3.1 Prospects for Monoclonal Antibodies and Implications for Drug Delivery
4.1.4 The Human Insulins Class Will Exhibit Strong Growth
4.1.5 Erythropoietin Products - What are the Future Prospects?
4.1.5.1 Erythropoietin Products Forecast, 2013-2023
4.1.6 The Interferons Class Will Show an Increase in Revenues from 2012-2017
4.1.6.1 Long-Term Forecast for the Interferons Class
4.1.7 Granular-Colony Stimulating Factors (G-CSF) Forecast, 2013-2023
4.1.8 Recombinant Coagulation Factors Will Show Steady Growth
4.1.9 Other Therapeutic Proteins
4.1.10 The Biosimilars Market, 2012
4.1.10.1 Forecast for the Global Biosimilars Market, 2013-2023
4.1.11 Forecast for the Vaccines Market, 2013-2023
4.2 The Drug Delivery Technology Market: Conclusions
4.2.1 A Rapidly Expanding Segment of the Global Pharma Industry
5. PROMINENT COMPANIES IN THE DRUG DELIVERY TECHNOLOGY MARKET
5.1 Introduction
5.2 Leading Oral Drug Delivery Companies
5.2.1 Applied Pharma Research (APR)
5.2.1.1 Overview
5.2.1.2 Therapeutic Areas and Technology
5.2.1.3 MonoSol Rx Enters into Licensing Agreement with Vestiq Pharmaceuticals for Zuplenz
5.2.2 Catalent Pharma Solutions
5.2.2.1 Overview
5.2.2.2 Catalent's Oral Drug Delivery Technology
5.2.2.3 Catalent's Customer Base
5.2.2.4 Manufacturing Capabilities
5.2.2.5 Revenues
5.2.2.6 Catalent Pharma Acquires Clinical Trial Supplies Business
5.2.2.7 Catalent's Actions and Progress in 2012
5.2.3 Emisphere Technologies
5.2.3.1 Overview
5.2.3.2 Emisphere's Eligen Technology
5.2.3.3 Emisphere's Pipeline Products
5.2.3.4 Emisphere's Partnered Programmes
5.2.3.5 Revenues
5.2.3.6 Future Outlook
5.2.4 Ethypharm
5.2.4.1 Overview
5.2.4.2 Ethypharm's Proprietary Technologies
5.2.4.3 Products on the Market
5.2.4.4 Development Pipeline
5.2.5 Aptalis
5.2.5.1 Overview
5.2.5.2 Aptalis's Drug Delivery Platforms
5.2.5.3 Products for Out-Licensing
5.2.5.4 Revenue
5.2.5.5 Future Outlook
5.2.6 Glycologic
5.2.6.1 Overview
5.2.6.2 Glycologic Technology Platform
5.2.6.3 Pipeline Products
5.2.6.4 Future Outlook
5.3 Inhaled Drug Delivery
5.3.1 3M Drug Delivery Systems
5.3.1.1 Overview
5.3.1.2 Protein and Peptide Delivery
5.3.1.3 Excipient Technology for CFC-Free Inhalers
5.3.1.4 Actuator Technology for MDIs
5.3.1.5 Particle Engineering Technology
5.3.1.6 Revenues
5.3.2 Aradigm Corp.
5.3.2.1Overview
5.3.2.2 AERx Drug Delivery System
5.3.2.3 Collaborations
5.3.2.4 Pipeline Products
5.3.2.5 Revenues
5.3.3 Vectura Group
5.3.3.1 Overview
5.3.3.2 Proprietary Technologies
5.3.3.3 Pipeline Products
5.3.3.4 Revenues
5.4 Injectable Drug Delivery
5.4.1 Alkermes
5.4.1.1Overview
5.4.1.2 Proprietary Technology Platforms
5.4.1.3 Product Pipeline
5.4.1.4 Revenues
5.4.2 Pacira Pharmaceuticals
5.4.2.1 Overview
5.4.2.2 Injectable Sustained-Release Technology
5.4.2.3 Products
5.4.2.4 Pipeline
5.4.2.5 Revenues
5.4.2.6 Future Outlook
5.4.3 Antares Pharma
5.4.3.1 Overview
5.4.3.2 Technology
5.4.3.2.1 Pressure Assisted Injection Devices
5.4.3.2.2 Transdermal Gel System
5.4.3.3 Products
5.4.3.3.1 Vision
5.4.3.3.2 Vibex
5.4.3.3.3 Pen Injector
5.4.3.4 Pipeline Technologies
5.4.3.4.1 Vibex MTX
5.4.3.5 Manufacturing
5.4.3.6 Revenues
5.4.3.7 Future Outlook
5.4.4 Bioject Medical Technologies
5.4.4.1 Technology
5.4.4.2 Products
5.4.4.2.1 Biojector 2000
5.4.4.2.2 Vitajet
5.4.4.2.3 ZetaJet
5.4.4.3 Pipeline Technologies
5.4.4.3.1 Intradermal Pen Injector
5.4.4.3.2 Iject
5.4.4.3.3 Jupiter Jet
5.4.4.4 Manufacturing
5.4.4.5 Collaborations
5.4.4.5.1 MPI Research
5.4.4.5.2 World Health Organization (WHO)
5.4.4.6 Revenues
5.5 Transdermal Drug Delivery
5.5.1 3M
5.5.1.1 Overview
5.5.1.2 Transdermal Systems
5.5.2 Altea Therapeutics
5.5.2.1 Overview
5.5.2.2 Altea's PassPort Technology Platform
5.5.2.3 Therapeutic Focus
5.5.2.4 Nitto Denko Acquires Altea Therapeutics Assets
5.5.3 Intercell
5.5.3.1 Overview
5.5.3.2 Vaccine Patch Technology Platform
5.5.3.3 Intercell's Strategic Alliances
5.5.3.4 Revenues
5.5.3.5 Future Outlook
5.5.4 NanoPass Technologies
5.5.4.1 Overview
5.5.4.2 Technology Platform
5.5.4.3 The MicronJet Needle
5.5.4.4 NanoCare
5.5.5 Noven Pharmaceuticals
5.5.5.1 Overview
5.5.5.2 Key Products
5.5.5.3 Transdermal Pipeline
5.5.5.4 Revenues
5.6 Transmucosal Drug Delivery
5.6.1 Overview of Technology
5.6.2 Cima Labs (Cephalon)
5.6.2.1 Overview
5.6.2.2 Cima's Transmucosal Drug Delivery Technologies
5.6.2.3 Products
5.6.3 Columbia Laboratories
5.6.3.1 Overview
5.6.3.2 Bioadhesive Delivery Technology
5.6.3.3 Products
5.6.3.4 Revenue
5.6.3.5 Future Outlook
5.6.4 Generex Biotechnology Corporation
5.6.4.1 Overview
5.6.4.2 Products
5.6.4.3 Pipeline Products
5.6.4.4 Revenue
5.7 Implant Technology
5.7.1 Overview of Technology
5.7.2 pSivida Corp.
5.7.2.1 Overview
5.7.2.2 Technologies and Products
5.7.2.2.1 Durasert Technology System
5.7.2.2.2 BioSilicon Technology System
5.7.2.2.3 CODRUG Technology System
5.7.2.3 Products
5.7.2.3.1 Iluvian Approved in Europe
5.7.2.4 Revenues
6. DRIVERS, RESTRAINTS AND TRENDS IN DRUG DELIVERY
6.1 Analysis of Strengths, Weaknesses, Opportunities and Threats (SWOT)
6.2 Patent Expiry Will Drive Biological Drug Delivery
6.2.1 Biosimilars Legislation Encourages Innovation
6.2.2 As Patents Expire, Competition Will Increase
6.3 Competitive and Lucrative Monoclonal Antibody Market Will Drive Sales
6.4 Biological Drug Delivery Technology is Already Established
6.4.1 Pegylation Has Imparted Benefits
6.4.2 New Delivery Methods for Insulin?
6.4.3 Nanotechnology Can Benefit Biological Drug Delivery
6.5 Will Regulatory Authorities Hold Back the Market?
6.5.1 Risk-Conscious FDA and EMA Will Make Approval Difficult?
6.5.2 Choice between New Technology or a New Drug? Is a Rethink Needed?
6.6 New Delivery Methods for Biologicals Must be Cost Effective and Appropriate
6.7 Injection is Still the Major Form of Delivery
6.8 Next-Generation Drugs May Limit Drug Delivery Revenues
6.8.1 Lifecycle Management via Protein Engineering Blurs Drug Delivery Lines
6.8.2 New Chemical Entities Could Restrict Biotech Growth
6.9 The Biological Drug Delivery Market Offers Great Potential, But Care is Needed
7. RESEARCH INTERVIEWS FROM OUR SURVEY
7.1 Professor Sven Fr°kjцr, Dean, Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark
7.1.1 Market Value for Drug Delivery Systems
7.1.2 Key Benefits for Patients
7.1.3 On Emerging Technologies
7.1.4 On Nanotechnology
7.1.5 On Different Systems
7.1.6 Main Challenges Facing the Sector
7.1.7 On Nanoparticle Systems and Drug Delivery
7.1.8 Systems on the Market
7.1.9 Diseases of Interest
7.1.10 Therapeutic Areas Offering Opportunities
7.2 Dr Bill Lambert, Ph.D., Senior Vice President, Pharmaceutical Development, Pacira Pharmaceuticals, San Diego, CA, USA
7.2.1 On Pacira and Drug Delivery Technology
7.2.2 Liposomal Drug Delivery
7.2.3 Applications of DepoFoam Technology
7.2.4 On Pacira's Products
7.2.5 Pipeline DDT Platforms
7.2.6 On the Market for Drug Delivery Technology
7.2.7 Therapeutic Areas Offering Market Opportunities
7.2.8 Challenges Facing Drug Delivery Industry
7.2.9 Comparing DepoFoam with Other Controlled-Release Systems
7.2.10 Mode of Delivery
7.2.11 Insulin and Liposomal Drug Delivery
7.2.12 R&D and Technologies Likely to be on Market in Future
7.3 Mr David Harris, Principal Consultant at Team Consulting Limited, UK
7.3.1 Current Market Value for Drug Delivery Systems
7.3.2 On Key Unmet Needs
7.3.3 On Research Focus in the Next 10-15 Years
7.3.4 On Main Challenges Facing the Sector
7.3.5 On Therapeutic Areas Offering Opportunities
7.3.6 On Pipeline Developments
7.4 Dr Ronan Mac Loughlin, Scientist at Aerogen, Galway, Ireland
7.4.1 Current Market Value for Drug Delivery Systems
7.4.2 On Aerogen and its Drug Delivery Systems
7.4.3 On Key Unmet Needs
7.4.4 On Research Focus in the Next 10-15 Years
7.4.5 On Main Challenges Facing the Sector
7.4.6 On Therapeutic Areas Offering Opportunities
7.4.7 On Pipeline Developments
7.5 Mr. John Turanin, VP and General Manager, Zogenix Technologies, CA, USA
7.5.1 On Current State of the Market
7.5.2 On Patient Awareness and Needle-free Injectable Technology
7.5.3 On JV/M&A and Zogenix
7.5.4 Zogenix's Product Portfolio and Technology
7.5.5 On Competing Technologies and Market Share
7.5.6 On Adoption of Zogenix's Technology
7.5.7 On The Future Needle-Free Injection Devices
7.5.8 On Major Challenges Facing Needle-Free Injection Devices
7.5.9 On Future Growth in the Sector
7.6 Mr. Charles Potter, CBO, Glide Pharma, Oxford, UK
7.6.1 On Growth and Market Potential
7.6.2 On Patient Power and DTC Marketing
7.6.3 Glide SDI & Other Technologies
7.6.4 On Competition from Transdermal & Inhalation Technologies
7.6.5 Market Demand & Future Outlook
7.6.6 On Future Technology Trends
7.6.7 On Future Market Potential
7.7 Ms. Heather Potters, Chairman, PharmaJet, Colorado, USA
7.7.1 On Needle-Free Drug Delivery Technology Market
7.7.2 On M&A and JV Strategy for Growth
7.7.3 On PharmaJet's Leading Products
7.7.4 On Equivalence of Fractional and Full Dose Delivery
7.7.5 Patient Awareness About Jet Injectors
7.7.6 Unmet Needs in the Jet Injectors Market
7.7.7 Major Challenges Faced by Jet Injectors Market
7.7.8 The Outlook for Needle-Free Technology Market
8. CONCLUSIONS OF OUR RESEARCH AND ANALYSES
8.1 The Market Shows Potential for Strong Revenue Growth
8.2 Commercial Drivers for Drug Delivery Technology
8.3 Prominent Companies in the Market
8.4 Future Outlook and Concluding Remarks
1.1 Drug Delivery Technology: Market Review
1.2 Aims, Scope and Format of Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods
2. INTRODUCTION
2.1 Introduction to Drug Delivery Technologies (DDT)
2.2 Types of Technologies for Drug Delivery
2.2.1 Sustained/Controlled Release Systems
2.2.2 Injection
2.2.3 Needle Free Injection
2.2.4 Pulmonary, Buccal and Nasal Delivery
2.2.5 Pills and Capsules
2.3 Biopharmaceuticals
2.3.1 Overview of the Biologicals Market
2.3.2 The Biological Drug Industry is Strong
2.4 Biotech Drugs with Associated Drug Delivery Technologies
2.4.1 Pegylated Interferons
2.4.2 Crowded Insulin Market Has Forced Investment in DDT
2.5 Exubera - Case Study for Alternative Biological Delivery Methods
2.5.1 The First Inhaled Insulin
2.5.2 Description and Development History
2.5.3 Generex and MannKind Developing Next-Generation Oral Insulins
2.5.4 Challenges Facing Afrezza and Oral-lyn
2.6 The Main Challenges for Biological Drug Delivery
3. THE WORLD DRUG DELIVERY TECHNOLOGY MARKET TO 2023
3.1 The World Drug Delivery Technology Market: Overview
3.2 Growing Market for Drug Delivery Technology and Services
3.2.1 Revenue Forecast for Overall Drug Delivery Technology Market, 2012-2017
3.2.2 Revenue Forecast for Overall Drug Delivery Market, 2018-2023
3.3 Breakdown of the Global Drug Delivery Technology Market
3.3.1 Revenue Forecast for Oral Drug Delivery Technology, 2012-2017
3.3.2 Revenue Forecast for Oral Drug Delivery Technology, 2018-2023
3.3.3 Revenue Forecast for Inhalation Drug Delivery Technology, 2012-2017
3.3.4 Revenue Forecast for Inhalation Drug Delivery Technology, 2018-2023
3.3.5 Revenue Forecast for Transdermal Drug Delivery Technology, 2012-2017
3.3.6 Revenue Forecast for Transdermal Drug Delivery Technology, 2018-2023
3.3.7 Revenue Forecast for Injectable/Implants Drug Delivery Technology, 2012-2017
3.3.8 Revenue Forecast for Injectable/Implants Drug Delivery Technology, 2018-2023
3.3.9 Revenue Forecast for Ocular Drug Delivery Technology, 2012-2017
3.3.10 Revenue Forecast for Ocular Drug Delivery Technology, 2018-2023
3.3.11 Revenue Forecast for Nasal Drug Delivery Technology, 2012-2017
3.3.12 Revenue Forecast for Nasal Drug Delivery Technology, 2018-2023
3.4 Leading National Markets for Drug Delivery Technology
3.4.1 The US Drug Delivery Technology Market, 2013-2023
3.4.2 The Japanese Drug Delivery Technology Market, 2013-2023
3.4.3 The Leading European Drug Delivery Technology Markets, 2013-2023
3.4.4 Emerging-Economy Drug Delivery Technology Markets
3.4.5 The Chinese Drug Delivery Technology Market, 2013-2023
3.4.6 The Indian Drug Delivery Technology Market, 2013-2023
4. DRUG CLASSES THAT CAN BENEFIT FROM ADVANCES IN DRUG DELIVERY
4.1 Therapeutic Areas Offering Growth Opportunities
4.1.1 Sales of Biologics Will Stimulate Developments in Drug Delivery
4.1.2 Leading Segments of Biological Drugs Market in 2012
4.1.3 Monoclonal Antibodies Lead the Biologics Market
4.1.3.1 Prospects for Monoclonal Antibodies and Implications for Drug Delivery
4.1.4 The Human Insulins Class Will Exhibit Strong Growth
4.1.5 Erythropoietin Products - What are the Future Prospects?
4.1.5.1 Erythropoietin Products Forecast, 2013-2023
4.1.6 The Interferons Class Will Show an Increase in Revenues from 2012-2017
4.1.6.1 Long-Term Forecast for the Interferons Class
4.1.7 Granular-Colony Stimulating Factors (G-CSF) Forecast, 2013-2023
4.1.8 Recombinant Coagulation Factors Will Show Steady Growth
4.1.9 Other Therapeutic Proteins
4.1.10 The Biosimilars Market, 2012
4.1.10.1 Forecast for the Global Biosimilars Market, 2013-2023
4.1.11 Forecast for the Vaccines Market, 2013-2023
4.2 The Drug Delivery Technology Market: Conclusions
4.2.1 A Rapidly Expanding Segment of the Global Pharma Industry
5. PROMINENT COMPANIES IN THE DRUG DELIVERY TECHNOLOGY MARKET
5.1 Introduction
5.2 Leading Oral Drug Delivery Companies
5.2.1 Applied Pharma Research (APR)
5.2.1.1 Overview
5.2.1.2 Therapeutic Areas and Technology
5.2.1.3 MonoSol Rx Enters into Licensing Agreement with Vestiq Pharmaceuticals for Zuplenz
5.2.2 Catalent Pharma Solutions
5.2.2.1 Overview
5.2.2.2 Catalent's Oral Drug Delivery Technology
5.2.2.3 Catalent's Customer Base
5.2.2.4 Manufacturing Capabilities
5.2.2.5 Revenues
5.2.2.6 Catalent Pharma Acquires Clinical Trial Supplies Business
5.2.2.7 Catalent's Actions and Progress in 2012
5.2.3 Emisphere Technologies
5.2.3.1 Overview
5.2.3.2 Emisphere's Eligen Technology
5.2.3.3 Emisphere's Pipeline Products
5.2.3.4 Emisphere's Partnered Programmes
5.2.3.5 Revenues
5.2.3.6 Future Outlook
5.2.4 Ethypharm
5.2.4.1 Overview
5.2.4.2 Ethypharm's Proprietary Technologies
5.2.4.3 Products on the Market
5.2.4.4 Development Pipeline
5.2.5 Aptalis
5.2.5.1 Overview
5.2.5.2 Aptalis's Drug Delivery Platforms
5.2.5.3 Products for Out-Licensing
5.2.5.4 Revenue
5.2.5.5 Future Outlook
5.2.6 Glycologic
5.2.6.1 Overview
5.2.6.2 Glycologic Technology Platform
5.2.6.3 Pipeline Products
5.2.6.4 Future Outlook
5.3 Inhaled Drug Delivery
5.3.1 3M Drug Delivery Systems
5.3.1.1 Overview
5.3.1.2 Protein and Peptide Delivery
5.3.1.3 Excipient Technology for CFC-Free Inhalers
5.3.1.4 Actuator Technology for MDIs
5.3.1.5 Particle Engineering Technology
5.3.1.6 Revenues
5.3.2 Aradigm Corp.
5.3.2.1Overview
5.3.2.2 AERx Drug Delivery System
5.3.2.3 Collaborations
5.3.2.4 Pipeline Products
5.3.2.5 Revenues
5.3.3 Vectura Group
5.3.3.1 Overview
5.3.3.2 Proprietary Technologies
5.3.3.3 Pipeline Products
5.3.3.4 Revenues
5.4 Injectable Drug Delivery
5.4.1 Alkermes
5.4.1.1Overview
5.4.1.2 Proprietary Technology Platforms
5.4.1.3 Product Pipeline
5.4.1.4 Revenues
5.4.2 Pacira Pharmaceuticals
5.4.2.1 Overview
5.4.2.2 Injectable Sustained-Release Technology
5.4.2.3 Products
5.4.2.4 Pipeline
5.4.2.5 Revenues
5.4.2.6 Future Outlook
5.4.3 Antares Pharma
5.4.3.1 Overview
5.4.3.2 Technology
5.4.3.2.1 Pressure Assisted Injection Devices
5.4.3.2.2 Transdermal Gel System
5.4.3.3 Products
5.4.3.3.1 Vision
5.4.3.3.2 Vibex
5.4.3.3.3 Pen Injector
5.4.3.4 Pipeline Technologies
5.4.3.4.1 Vibex MTX
5.4.3.5 Manufacturing
5.4.3.6 Revenues
5.4.3.7 Future Outlook
5.4.4 Bioject Medical Technologies
5.4.4.1 Technology
5.4.4.2 Products
5.4.4.2.1 Biojector 2000
5.4.4.2.2 Vitajet
5.4.4.2.3 ZetaJet
5.4.4.3 Pipeline Technologies
5.4.4.3.1 Intradermal Pen Injector
5.4.4.3.2 Iject
5.4.4.3.3 Jupiter Jet
5.4.4.4 Manufacturing
5.4.4.5 Collaborations
5.4.4.5.1 MPI Research
5.4.4.5.2 World Health Organization (WHO)
5.4.4.6 Revenues
5.5 Transdermal Drug Delivery
5.5.1 3M
5.5.1.1 Overview
5.5.1.2 Transdermal Systems
5.5.2 Altea Therapeutics
5.5.2.1 Overview
5.5.2.2 Altea's PassPort Technology Platform
5.5.2.3 Therapeutic Focus
5.5.2.4 Nitto Denko Acquires Altea Therapeutics Assets
5.5.3 Intercell
5.5.3.1 Overview
5.5.3.2 Vaccine Patch Technology Platform
5.5.3.3 Intercell's Strategic Alliances
5.5.3.4 Revenues
5.5.3.5 Future Outlook
5.5.4 NanoPass Technologies
5.5.4.1 Overview
5.5.4.2 Technology Platform
5.5.4.3 The MicronJet Needle
5.5.4.4 NanoCare
5.5.5 Noven Pharmaceuticals
5.5.5.1 Overview
5.5.5.2 Key Products
5.5.5.3 Transdermal Pipeline
5.5.5.4 Revenues
5.6 Transmucosal Drug Delivery
5.6.1 Overview of Technology
5.6.2 Cima Labs (Cephalon)
5.6.2.1 Overview
5.6.2.2 Cima's Transmucosal Drug Delivery Technologies
5.6.2.3 Products
5.6.3 Columbia Laboratories
5.6.3.1 Overview
5.6.3.2 Bioadhesive Delivery Technology
5.6.3.3 Products
5.6.3.4 Revenue
5.6.3.5 Future Outlook
5.6.4 Generex Biotechnology Corporation
5.6.4.1 Overview
5.6.4.2 Products
5.6.4.3 Pipeline Products
5.6.4.4 Revenue
5.7 Implant Technology
5.7.1 Overview of Technology
5.7.2 pSivida Corp.
5.7.2.1 Overview
5.7.2.2 Technologies and Products
5.7.2.2.1 Durasert Technology System
5.7.2.2.2 BioSilicon Technology System
5.7.2.2.3 CODRUG Technology System
5.7.2.3 Products
5.7.2.3.1 Iluvian Approved in Europe
5.7.2.4 Revenues
6. DRIVERS, RESTRAINTS AND TRENDS IN DRUG DELIVERY
6.1 Analysis of Strengths, Weaknesses, Opportunities and Threats (SWOT)
6.2 Patent Expiry Will Drive Biological Drug Delivery
6.2.1 Biosimilars Legislation Encourages Innovation
6.2.2 As Patents Expire, Competition Will Increase
6.3 Competitive and Lucrative Monoclonal Antibody Market Will Drive Sales
6.4 Biological Drug Delivery Technology is Already Established
6.4.1 Pegylation Has Imparted Benefits
6.4.2 New Delivery Methods for Insulin?
6.4.3 Nanotechnology Can Benefit Biological Drug Delivery
6.5 Will Regulatory Authorities Hold Back the Market?
6.5.1 Risk-Conscious FDA and EMA Will Make Approval Difficult?
6.5.2 Choice between New Technology or a New Drug? Is a Rethink Needed?
6.6 New Delivery Methods for Biologicals Must be Cost Effective and Appropriate
6.7 Injection is Still the Major Form of Delivery
6.8 Next-Generation Drugs May Limit Drug Delivery Revenues
6.8.1 Lifecycle Management via Protein Engineering Blurs Drug Delivery Lines
6.8.2 New Chemical Entities Could Restrict Biotech Growth
6.9 The Biological Drug Delivery Market Offers Great Potential, But Care is Needed
7. RESEARCH INTERVIEWS FROM OUR SURVEY
7.1 Professor Sven Fr°kjцr, Dean, Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark
7.1.1 Market Value for Drug Delivery Systems
7.1.2 Key Benefits for Patients
7.1.3 On Emerging Technologies
7.1.4 On Nanotechnology
7.1.5 On Different Systems
7.1.6 Main Challenges Facing the Sector
7.1.7 On Nanoparticle Systems and Drug Delivery
7.1.8 Systems on the Market
7.1.9 Diseases of Interest
7.1.10 Therapeutic Areas Offering Opportunities
7.2 Dr Bill Lambert, Ph.D., Senior Vice President, Pharmaceutical Development, Pacira Pharmaceuticals, San Diego, CA, USA
7.2.1 On Pacira and Drug Delivery Technology
7.2.2 Liposomal Drug Delivery
7.2.3 Applications of DepoFoam Technology
7.2.4 On Pacira's Products
7.2.5 Pipeline DDT Platforms
7.2.6 On the Market for Drug Delivery Technology
7.2.7 Therapeutic Areas Offering Market Opportunities
7.2.8 Challenges Facing Drug Delivery Industry
7.2.9 Comparing DepoFoam with Other Controlled-Release Systems
7.2.10 Mode of Delivery
7.2.11 Insulin and Liposomal Drug Delivery
7.2.12 R&D and Technologies Likely to be on Market in Future
7.3 Mr David Harris, Principal Consultant at Team Consulting Limited, UK
7.3.1 Current Market Value for Drug Delivery Systems
7.3.2 On Key Unmet Needs
7.3.3 On Research Focus in the Next 10-15 Years
7.3.4 On Main Challenges Facing the Sector
7.3.5 On Therapeutic Areas Offering Opportunities
7.3.6 On Pipeline Developments
7.4 Dr Ronan Mac Loughlin, Scientist at Aerogen, Galway, Ireland
7.4.1 Current Market Value for Drug Delivery Systems
7.4.2 On Aerogen and its Drug Delivery Systems
7.4.3 On Key Unmet Needs
7.4.4 On Research Focus in the Next 10-15 Years
7.4.5 On Main Challenges Facing the Sector
7.4.6 On Therapeutic Areas Offering Opportunities
7.4.7 On Pipeline Developments
7.5 Mr. John Turanin, VP and General Manager, Zogenix Technologies, CA, USA
7.5.1 On Current State of the Market
7.5.2 On Patient Awareness and Needle-free Injectable Technology
7.5.3 On JV/M&A and Zogenix
7.5.4 Zogenix's Product Portfolio and Technology
7.5.5 On Competing Technologies and Market Share
7.5.6 On Adoption of Zogenix's Technology
7.5.7 On The Future Needle-Free Injection Devices
7.5.8 On Major Challenges Facing Needle-Free Injection Devices
7.5.9 On Future Growth in the Sector
7.6 Mr. Charles Potter, CBO, Glide Pharma, Oxford, UK
7.6.1 On Growth and Market Potential
7.6.2 On Patient Power and DTC Marketing
7.6.3 Glide SDI & Other Technologies
7.6.4 On Competition from Transdermal & Inhalation Technologies
7.6.5 Market Demand & Future Outlook
7.6.6 On Future Technology Trends
7.6.7 On Future Market Potential
7.7 Ms. Heather Potters, Chairman, PharmaJet, Colorado, USA
7.7.1 On Needle-Free Drug Delivery Technology Market
7.7.2 On M&A and JV Strategy for Growth
7.7.3 On PharmaJet's Leading Products
7.7.4 On Equivalence of Fractional and Full Dose Delivery
7.7.5 Patient Awareness About Jet Injectors
7.7.6 Unmet Needs in the Jet Injectors Market
7.7.7 Major Challenges Faced by Jet Injectors Market
7.7.8 The Outlook for Needle-Free Technology Market
8. CONCLUSIONS OF OUR RESEARCH AND ANALYSES
8.1 The Market Shows Potential for Strong Revenue Growth
8.2 Commercial Drivers for Drug Delivery Technology
8.3 Prominent Companies in the Market
8.4 Future Outlook and Concluding Remarks
LIST OF TABLES
Table 2.1 Top 10 Biotech Drugs, 2012
Table 2.2 Top 10 Biopharma Companies: Revenues & R&D Expenditure, 2011
Table 2.3 Amino Acid Changes for Human Insulin Analogues
Table 3.1 Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.2 Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.3 Oral Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.4 Oral Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.5 Inhalation Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.6 Inhalation Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.7 Transdermal DDT Market: World Revenues, 2012-2017
Table 3.8 Transdermal DDT Market: World Revenues, 2018-2023
Table 3.9 Injectable/Implants DDT Market: World Revenues, 2012-2017
Table 3.10 Injectable/Implants DDT Market: World Revenues, 2018-2023
Table 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.15 Drug Delivery Technology Submarkets: World Revenues, 2012-2017
Table 3.16 Drug Delivery Technology Submarkets: World Revenues, 2018-2023
Table 3.17 Drug Delivery Technology: Leading National Market Forecasts, 2012-2023
Table 4.1 Leading Drug Classes Driving the Drug Delivery Technology Market, 2011 and 2012
Table 4.2 Some Leading Monoclonal Antibody Drugs, 2013
Table 4.3 Monoclonal Antibodies Market: World Sales Forecast, 2012-2017
Table 4.4 Monoclonal Antibodies Market: World Sales Forecast, 2018-2023
Table 4.5 Insulins Market: World Sales Forecast, 2012-2017
Table 4.6 Insulins Market: World Sales Forecast, 2018-2023
Table 4.7 Erythropoietins Market: World Sales Forecast, 2012-2017
Table 4.8 Erythropoietins Market: World Sales Forecast, 2018-2023
Table 4.9 Some Interferon Drugs, 2013
Table 4.10 Interferons Market: World Sales Forecast, 2012-2017
Table 4.11 Interferons Market: World Sales Forecast, 2018-2023
Table 4.12 G-CSF Market: World Sales Forecast, 2012-2017
Table 4.13 G-CSF Market: World Sales Forecast, 2018-2023
Table 4.14 Some Recombinant Coagulation Factors, 2013
Table 4.15 Recombinant Coagulation Factors Market: World Sales Forecast, 2012-2017
Table 4.16 Recombinant Coagulation Factors Market: World Sales Forecast, 2018-2023
Table 4.17 Some Human Growth Hormones, 2013
Table 4.18 Some Immunosuppressant Products, 2013
Table 4.19 Other Therapeutic Proteins Market: World Sales Forecast, 2012-2017
Table 4.20 Other Therapeutic Proteins Market: World Sales Forecast, 2018-2023
Table 4.21 Some Biosimilar Drugs, 2013
Table 4.22 Biosimilars Market: World Sales Forecast, 2012-2017
Table 4.23 Biosimilars Market: World Sales Forecast, 2018-2023
Table 4.24 Some Vaccines Products, 2013
Table 4.25 Vaccines Market: World Sales Forecast, 2012-2017
Table 4.26 Vaccines Market: World Sales Forecast, 2018-2023
Table 5.1 Aradigm's Product Pipeline, 2013
Table 5.2 Alkermes' Product Pipeline, 2013
Table 5.3 Antares Pharma Licensing Partnerships, 2013
Table 5.4 Antares Pharma: Summary of Technology, 2013
Table 5.5 Bioject: Summary of Technologies, 2013
Table 5.6 Intercell's Strategic Alliances, 2013
Table 5.7 Noven's Marketed & Pipeline Transdermal Products, 2013
Table 6.1 SWOT Analysis of the Drug Delivery Industry and Market, 2013
Table 6.2 Some Leading Drugs Expected to Lose Patent Protection, 2012-2015
Table 6.3 Monoclonal Antibody Therapies Approved by the US FDA, 1986-2003
Table 6.4 Monoclonal Antibody Therapies Approved by the US FDA, 2004-2010
Table 6.5 Leading Biologic Drug Types, 2012
Table 8.1 Drug Delivery Technology Market: World Revenues, 2012, 2013, 2017, 2019, 2021 & 2023
Table 2.1 Top 10 Biotech Drugs, 2012
Table 2.2 Top 10 Biopharma Companies: Revenues & R&D Expenditure, 2011
Table 2.3 Amino Acid Changes for Human Insulin Analogues
Table 3.1 Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.2 Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.3 Oral Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.4 Oral Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.5 Inhalation Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.6 Inhalation Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.7 Transdermal DDT Market: World Revenues, 2012-2017
Table 3.8 Transdermal DDT Market: World Revenues, 2018-2023
Table 3.9 Injectable/Implants DDT Market: World Revenues, 2012-2017
Table 3.10 Injectable/Implants DDT Market: World Revenues, 2018-2023
Table 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2012-2017
Table 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2018-2023
Table 3.15 Drug Delivery Technology Submarkets: World Revenues, 2012-2017
Table 3.16 Drug Delivery Technology Submarkets: World Revenues, 2018-2023
Table 3.17 Drug Delivery Technology: Leading National Market Forecasts, 2012-2023
Table 4.1 Leading Drug Classes Driving the Drug Delivery Technology Market, 2011 and 2012
Table 4.2 Some Leading Monoclonal Antibody Drugs, 2013
Table 4.3 Monoclonal Antibodies Market: World Sales Forecast, 2012-2017
Table 4.4 Monoclonal Antibodies Market: World Sales Forecast, 2018-2023
Table 4.5 Insulins Market: World Sales Forecast, 2012-2017
Table 4.6 Insulins Market: World Sales Forecast, 2018-2023
Table 4.7 Erythropoietins Market: World Sales Forecast, 2012-2017
Table 4.8 Erythropoietins Market: World Sales Forecast, 2018-2023
Table 4.9 Some Interferon Drugs, 2013
Table 4.10 Interferons Market: World Sales Forecast, 2012-2017
Table 4.11 Interferons Market: World Sales Forecast, 2018-2023
Table 4.12 G-CSF Market: World Sales Forecast, 2012-2017
Table 4.13 G-CSF Market: World Sales Forecast, 2018-2023
Table 4.14 Some Recombinant Coagulation Factors, 2013
Table 4.15 Recombinant Coagulation Factors Market: World Sales Forecast, 2012-2017
Table 4.16 Recombinant Coagulation Factors Market: World Sales Forecast, 2018-2023
Table 4.17 Some Human Growth Hormones, 2013
Table 4.18 Some Immunosuppressant Products, 2013
Table 4.19 Other Therapeutic Proteins Market: World Sales Forecast, 2012-2017
Table 4.20 Other Therapeutic Proteins Market: World Sales Forecast, 2018-2023
Table 4.21 Some Biosimilar Drugs, 2013
Table 4.22 Biosimilars Market: World Sales Forecast, 2012-2017
Table 4.23 Biosimilars Market: World Sales Forecast, 2018-2023
Table 4.24 Some Vaccines Products, 2013
Table 4.25 Vaccines Market: World Sales Forecast, 2012-2017
Table 4.26 Vaccines Market: World Sales Forecast, 2018-2023
Table 5.1 Aradigm's Product Pipeline, 2013
Table 5.2 Alkermes' Product Pipeline, 2013
Table 5.3 Antares Pharma Licensing Partnerships, 2013
Table 5.4 Antares Pharma: Summary of Technology, 2013
Table 5.5 Bioject: Summary of Technologies, 2013
Table 5.6 Intercell's Strategic Alliances, 2013
Table 5.7 Noven's Marketed & Pipeline Transdermal Products, 2013
Table 6.1 SWOT Analysis of the Drug Delivery Industry and Market, 2013
Table 6.2 Some Leading Drugs Expected to Lose Patent Protection, 2012-2015
Table 6.3 Monoclonal Antibody Therapies Approved by the US FDA, 1986-2003
Table 6.4 Monoclonal Antibody Therapies Approved by the US FDA, 2004-2010
Table 6.5 Leading Biologic Drug Types, 2012
Table 8.1 Drug Delivery Technology Market: World Revenues, 2012, 2013, 2017, 2019, 2021 & 2023
Visiongain believes that this class will show steady, low single-digit growth throughout the forecast period, 2013 to 2023. Revenues will increase to $5.67bn in 2017 and $6.04bn in 2023. The initial growth of sales in this class will be due to steady increases in sales of the current leading drugs. The introduction of new drugs will also contribute to growth of this class, our analyses reveal. That product category will be a main revenue growth driver for drug delivery technologies – products and services.
Other categories of therapeutic proteins include the following:
- Human growth hormones
- Immunosuppressant proteins
- Enzyme replacements
- Follicle stimulating hormones
